<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631020</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1042</article-id><article-id pub-id-type="publisher-id">ofx163.1042</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Fauqued</surname><given-names>Marta</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Campora</surname><given-names>Laura</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Delannois</surname><given-names>Fr&#x000e9;d&#x000e9;rique</given-names></name><degrees>DVM</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>El Idrissi</surname><given-names>Mohamed</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ledent</surname><given-names>Edouard</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Diez-Domingo</surname><given-names>Javier</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>McElhaney</surname><given-names>Janet</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>McNeil</surname><given-names>Shelly</given-names></name><degrees>MD, FRCPC, FIDSA</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>De Looze</surname><given-names>Ferdinandus</given-names></name><degrees>MBBS</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Yeo</surname><given-names>Wilfred</given-names></name><degrees>MB, ChB, MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Fernanda Tavares Da</given-names></name><degrees>MD, ObGvn</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><collab>ZOE-50/70 Study Group</collab><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>GSK</institution>, <addr-line>Wavre</addr-line>, <country>Belgium</country></aff><aff id="AF0002">
<label>2</label>
<institution>GSK</institution>, <addr-line>Rixensart</addr-line>, <country>Belgium</country></aff><aff id="AF0003">
<label>3</label>
<institution>Vaccine Research Unit, Fundaci&#x000f3;n para el Fomento de la Investigaci&#x000f3;n Sanitaria y Biom&#x000e9;dica</institution>, <addr-line>Valencia</addr-line>, <country>Spain</country></aff><aff id="AF0004">
<label>4</label>
<institution>Health Sciences North Research Institute</institution>, <addr-line>Sudbury, ON</addr-line>, <country>Canada</country></aff><aff id="AF0005">
<label>5</label>
<institution>Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University</institution>, <addr-line>Halifax, NS</addr-line>, <country>Canada</country></aff><aff id="AF0006">
<label>6</label>
<institution>University of Queensland</institution>, <addr-line>Queensland</addr-line>, <country>Australia</country></aff><aff id="AF0007">
<label>7</label>
<institution>School of Medicine, University of Wollongong</institution>, <addr-line>Wollongong</addr-line>, <country>Australia</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 152. Herpes Zoster Vaccine</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S416</fpage><lpage>S416</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1042.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The recombinant herpes zoster (HZ) subunit vaccine (HZ/su) has shown efficacy against HZ in adults &#x02265;50 and &#x02265;70 years of age (YOA), in two pivotal Phase III clinical trials (NCT01165177, NCT01165229). A pooled safety analysis of data from these two efficacy studies was performed, including a comparative analysis on HZ/su vs. placebo groups, to provide a comprehensive understanding of the HZ/su safety profile.</p></sec><sec id="s2"><title>Methods</title><p>Two pivotal, randomized, placebo-controlled Phase III studies, assessed the efficacy, reactogenicity and safety of HZ/su, administered intramuscularly according to a 0, 2-month schedule. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each dose, respectively; serious AEs (SAEs) for 1 year after last dose; fatal and related SAEs and potential immune-mediated diseases (pIMDs) during the entire study period. Reactogenicity was assessed in a subset of participants; safety was assessed in all vaccinated participants.</p></sec><sec id="s3"><title>Results</title><p>29,305 participants &#x02265;50 YOA (HZ/su: 14,645; placebo: 14,660) were included in the pooled analysis. HZ/su was more reactogenic than placebo. Local reactions were mostly mild to moderate in intensity and transient (median duration = 3 days); the percentages of participants reporting SAEs, fatal SAEs and pIMDs were similar in both groups, at 30 days and 1 year after last dose (Figures 1 and 2). Percentages of fatal SAEs ranged between 4.3% (95% Confidence Interval [CI]: 4.0&#x02013;4.7) and 4.6% (95% CI: 4.3&#x02013;5.0) and pIMDs between 1.2% (95% CI: 1.1&#x02013;1.4) and 1.4% (95% CI: 1.2&#x02013;1.6), in HZ/su and placebo groups, respectively. In both groups, the most frequent causes of death were neoplasms, cardiac disorders, and respiratory tract infections and infestations, and most frequent pIMDs were polymyalgia rheumatica, rheumatoid arthritis and psoriasis.</p></sec><sec id="s4"><title>Conclusion</title><p>No safety concern was identified. Together with the high efficacy against HZ (97.2% [95% CI: 93.7&#x02013;99.0],<sup>1</sup> 91.3% [95% CI: 86.8&#x02013;94.5]<sup>2</sup>), the safety data supports a favorable benefit/risk profile of HZ/su in participants &#x02265;50 YOA.</p></sec><sec id="s6"><title>Funding</title><p>GlaxoSmithKline Biologicals SA</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0456"/></fig><fig fig-type="figure" id="F2" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0457"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>M. L&#x000f3;pez-Fauqued</bold>, GSK Biologicals&#x02019;: Employee, Salary; <bold>&#x02028;L. Campora</bold>, GSK Biologicals&#x02019;: Employee, Salary; <bold>F. Delannois</bold>, GSK Vaccines: Employee, Salary; <bold>M. El Idrissi</bold>, GSK Vaccines: Employee, Salary; <bold>E. Ledent</bold>, GSK Vaccines: Employee, Salary; <bold>J. Diez-Domingo</bold>, GSK Vaccines: Consultant and Investigator, Educational support and Research grant; <bold>J. McElhaney</bold>, GSK Vaccines: Scientific Advisor, Speaker honorarium; <bold>S. McNeil</bold>, GSK/Merck: Grant Investigator, Investigator and Scientific Advisor, Consulting fee, Grant recipient, Research grant, Research support and Speaker honorarium; <bold>F. De Looze</bold>, GSK Vaccines: Investigator and Research Contractor, Research support; <bold>F. Tavares Da Silva</bold>, GSK Vaccines: Employee, restricted shares and Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>